NASDAQ:PNT - POINT Biopharma Global Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $17.00
  • Forecasted Upside: 128.49 %
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$7.44
▲ +0.34 (4.79%)

This chart shows the closing price for PNT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New POINT Biopharma Global Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PNT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PNT

Analyst Price Target is $17.00
▲ +128.49% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for POINT Biopharma Global in the last 3 months. The average price target is $17.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 128.49% upside from the last price of $7.44.

This chart shows the closing price for PNT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in POINT Biopharma Global. This rating has held steady since November 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/30/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/26/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
2/24/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
4/25/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
5/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2022Piper SandlerLower Price TargetNA$17.00 ➝ $14.00Low
12/17/2021MizuhoInitiated CoverageUnderperform$65.00High
12/1/2021Brookline Capital AcquisitionInitiated CoverageBuy$23.00Low
12/1/2021Brookline Capital ManagementReiterated RatingBuy$23.00Medium
7/29/2021CowenInitiated CoverageOutperformHigh
7/27/2021Jefferies Financial GroupInitiated CoverageHold$8.00Low
7/26/2021Piper SandlerInitiated CoverageOverweight$17.00Medium
(Data available from 5/25/2017 forward)

News Sentiment Rating

-0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/27/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/26/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/24/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/26/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
5/25/2022

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
POINT Biopharma Global logo
POINT Biopharma Global Inc., a late-stage clinical precision oncology company, focuses on the development and commercialization of radiopharmaceuticals for the treatment of cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer; and PNT-2004, a fibroblast activation protein-a targeted radioligand to treat solid tumors. POINT Biopharma Global Inc. is based in Indianapolis, Indiana.
Read More

Today's Range

Now: $7.44
Low: $6.83
High: $7.70

50 Day Range

MA: $7.63
Low: $5.60
High: $9.50

52 Week Range

Now: $7.44
Low: $4.25
High: $11.72

Volume

515,510 shs

Average Volume

295,620 shs

Market Capitalization

$670.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of POINT Biopharma Global?

The following Wall Street analysts have issued research reports on POINT Biopharma Global in the last twelve months: Brookline Capital Acquisition Corp., Brookline Capital Management, Cowen Inc, Jefferies Financial Group Inc., Mizuho, Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for PNT.

What is the current price target for POINT Biopharma Global?

0 Wall Street analysts have set twelve-month price targets for POINT Biopharma Global in the last year. Their average twelve-month price target is $17.00, suggesting a possible upside of 128.5%.
View the latest price targets for PNT.

What is the current consensus analyst rating for POINT Biopharma Global?

POINT Biopharma Global currently has 1 sell rating, 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PNT, but not buy more shares or sell existing shares.
View the latest ratings for PNT.

How do I contact POINT Biopharma Global's investor relations team?

POINT Biopharma Global's physical mailing address is 200 BERKELEY STREET 18TH FLOOR, BOSTON MA, 02116. The company's listed phone number is 64-7812-2417. The official website for POINT Biopharma Global is www.pointbiopharma.com. Learn More about contacing POINT Biopharma Global investor relations.